0001415889-23-002162.txt : 20230208
0001415889-23-002162.hdr.sgml : 20230208
20230208163640
ACCESSION NUMBER: 0001415889-23-002162
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230206
FILED AS OF DATE: 20230208
DATE AS OF CHANGE: 20230208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ezickson Elan
CENTRAL INDEX KEY: 0001486429
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36576
FILM NUMBER: 23599655
MAIL ADDRESS:
STREET 1: AVEO PHARMACEUTICALS, INC.
STREET 2: 75 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MARINUS PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001267813
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 RADNOR CORPORATE CENTER SUITE 500
STREET 2: 100 MATSONFORD RD
CITY: RADNOR
STATE: PA
ZIP: 19087
BUSINESS PHONE: 484-801-4670
MAIL ADDRESS:
STREET 1: 5 RADNOR CORPORATE CENTER SUITE 500
STREET 2: 100 MATSONFORD RD
CITY: RADNOR
STATE: PA
ZIP: 19087
FORMER COMPANY:
FORMER CONFORMED NAME: MARINUS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20031022
4
1
form4-02082023_090232.xml
X0306
4
2023-02-06
0001267813
MARINUS PHARMACEUTICALS, INC.
MRNS
0001486429
Ezickson Elan
5 RADNOR CORPORATE CENTER, SUITE 500
100 MATSONFORD RD
RADNOR
PA
19087
true
false
false
false
Common Stock
2023-02-06
4
S
0
750
6.56
D
5600
D
The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 plan to cover tax obligations in connection with the vesting of previously granted restricted stock units.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.55 - $6.56, inclusive. The
reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
/s/ Debra A. Mohollen, Attorney-in-Fact
2023-02-08